Online inquiry

IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5945MR)

This product GTTS-WQ5945MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Allergic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5945MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5210MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ7186MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ12522MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ9498MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ13100MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ1742MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ6543MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ11744MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW